A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Hidradenitis Suppurativa

In brief

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

Key facts

Study ID

NCT06046729

Run by

Eli Lilly and Company

People needed

352

Starts

2023-10-23

Expected to finish

2026-08-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a diagnosis of HS for at least 12 months.
• Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
• Have an (abscess plus inflammatory nodule) count of at least 5.
• Agree to use topical antiseptics daily.
• Had an inadequate response or intolerance to a 28-day course of oral antibiotics.

You may not qualify if…

• Have more than 20 draining fistulae.
• Have had surgical treatment for HS in the last 4 weeks before randomization.
• Have an active skin disease or condition, that could interfere with the assessment of HS.
• Have a current or recent acute, active infection.
• Are immunocompromised.
• Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Where it is running

• Saguaro Dermatology Associates, LLC - Probity - PPDS — Phoenix, Arizona, United States
• Arkansas Research Trials, LLC — North Little Rock, Arkansas, United States
• Northwest Arkansas Clinical Trials Center — Rogers, Arkansas, United States
• First OC Dermatology Research Inc — Fountain Valley, California, United States
• Center For Dermatology Clinical Research, Inc. — Fremont, California, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Dermatology Institute and Skin Care Center — Santa Monica, California, United States
• University of Connecticut — Farmington, Connecticut, United States
• Direct Helpers Research Center — Hialeah, Florida, United States
• University of Miami — Miami, Florida, United States
• Skin Research of South Florida — Miami, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Alliance Clinical Research of Tampa — Tampa, Florida, United States
• Olympian Clinical Research — Tampa, Florida, United States
• Advanced Medical Research, PC — Sandy Springs, Georgia, United States
• NorthShore Medical Group Dermatology - Skokie — Skokie, Illinois, United States
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
• Equity Medical - Bowling Green — Bowling Green, Kentucky, United States
• Derm Research LLC — Louisville, Kentucky, United States
• Care Access-Marriottsville — Marriottsville, Maryland, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Revival Research Institute - Troy — Troy, Michigan, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Skin Specialists, P.C — Omaha, Nebraska, United States
• Medical Dermatology Specialists — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.